Ameriprise
SABS icon

Ameriprise’s SAB Biotherapeutics SABS Stock Holding History

Ameriprise’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Sell
611,019
-865,087
-59% -$3.22M ﹤0.01% 2986
2026
Q1 		$5.65M Buy
1,476,106
+1,192,461
+420% +$4.75M ﹤0.01% 2354
2025
Q4 		$1.06M Buy
+283,645
New +$933K ﹤0.01% 3302

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ameriprise's SABS Position: Q2 2026 in Review

Ameriprise reduced its SAB Biotherapeutics (SABS) stake by 59% in Q2 2026, selling an estimated $3.22M and leaving 611,019 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2986.

Ameriprise first reported a position in SABS in Q4 2025 and has held it in 3 quarters since. The position peaked at $5.65M in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Ameriprise held 611,019 shares of SAB Biotherapeutics worth $2.38M as of Q2 2026.
  • Ameriprise sold 865,087 SAB Biotherapeutics shares in Q2 2026, an estimated $3.22M.
  • SAB Biotherapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2986 holding.
  • Ameriprise first reported a position in SAB Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Ameriprise's SAB Biotherapeutics position peaked at $5.65M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.